BofA lowered the firm’s price target on TPG (TPG) to $58 from $60 and keeps a Buy rating on the shares. Despite a tough backdrop, TPG monetized $9B in investments including One Oncology and Intersect Power, which contributed to the strength in transaction/capital markets fees, the analyst tells investors in a research note. The firm added that software exposure is limited in private credit.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPG:
